Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)

Karyopharm Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $200000.0 for Q3 2021.

For Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $200000.0; the TTM value through Mar 2022 reached $382000.0, down 7.06%, while the annual FY2020 figure was $329000.0, N/A changed from the prior year.
Asset Writedowns and Impairment reached $200000.0 in Q3 2021 per KPTI's latest filing, up from $100000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $329000.0 in Q4 2020 to a low of $82000.0 in Q1 2021.